Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Be6A Lung-01: Sigvotatug vedotin vs docetaxel in previously treated non-small cell lung cancer
ChiCTR2600128203Phase 3Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sigvotatug vedotin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Overall Survival (OS), Progression-Free Survival (PFS) by BICR and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
sigvotatug vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600128203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128203.